Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Innate Pharma (IPHA) EBITDA Margin (2020 - 2024)

Innate Pharma posted quarterly EBITDA Margin of 423.44% for Q4 2024, down 40531.0% year-on-year from N/an in Q1 2024, and down 33.45% on a QoQ basis from 317.29% in Q2 2024.

Innate Pharma (IPHA) has 5 years of EBITDA Margin data on file, last reported at 423.44% in Q4 2024.

  • For the quarter ending Q4 2024, EBITDA Margin fell 40531.0% year-over-year to 423.44%; the trailing twelve-month figure through Dec 2024 stood at 82.23% (down 4622.0% YoY), and the FY2025 full-year result was 1937.85%, down 168153.0% from the prior year.
  • EBITDA Margin for Q4 2024 stood at 423.44%, down from 317.29% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 0.11% in Q4 2022 and bottomed at 423.44% in Q4 2024.
  • The 5-year median for EBITDA Margin is 18.12% (2023), against an average of 138.17%.
  • The widest annual swing landed in 2022, when EBITDA Margin jumped 19349 bps; it then sank 40531 bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 13.52% in 2020, then tumbled by 1332 bps to 193.6% in 2021, then soared by 100 bps to 0.11% in 2022, then tumbled by 16412 bps to 18.12% in 2023, then plunged by 2237 bps to 423.44% in 2024.
  • The last three EBITDA Margin figures came in at 423.44% (Q4 2024), 317.29% (Q2 2024), and 18.12% (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 38.10%
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 18.35%
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 17.24%
10 Innate Pharma 199.64 Mn 199.64 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 -423.44%
Jun 30, 2024 -317.29%
Dec 31, 2023 -18.12%
Jun 30, 2023 -1.13%
Dec 31, 2022 -0.11%
Dec 31, 2021 -193.60%
Dec 31, 2020 -13.52%